Treatment outcome of NLPHL and cHL patients in the German Hodgkin Study Group.
| . | NLPHL (n= 394) . | cHL (n= 7904) . |
|---|---|---|
| Abbreviations: NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; cHL, classical Hodgkin lymphoma; FFTF, freedom from treatment failure; OS, overall survival | ||
| Progress (%) | .03 | 3.7 |
| Relapse (%) | 8.1 | 7.9 |
| Secondary Malignancies (%) | 2.5 | 3.7 |
| Death (%) | 4.3 | 8.8 |
| FFTF (%) | 88 | 82 |
| OS (%) | 96 | 92 |
| Median follow-up (months) | 41 | 48 |
| . | NLPHL (n= 394) . | cHL (n= 7904) . |
|---|---|---|
| Abbreviations: NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; cHL, classical Hodgkin lymphoma; FFTF, freedom from treatment failure; OS, overall survival | ||
| Progress (%) | .03 | 3.7 |
| Relapse (%) | 8.1 | 7.9 |
| Secondary Malignancies (%) | 2.5 | 3.7 |
| Death (%) | 4.3 | 8.8 |
| FFTF (%) | 88 | 82 |
| OS (%) | 96 | 92 |
| Median follow-up (months) | 41 | 48 |